Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S274000, C514S428000, C514S458000, C514S561000, C514S562000, C514S564000, C514S567000, C514S568000, C514S763000
Reexamination Certificate
active
06974833
ABSTRACT:
Methods for the treatment of diseases or pathological states related to the degradation of the extracellular matrix, such as degenerative diseases atheriosclerosis, cancer, infection or other inflammatory diseases are disclosed, comprising administering compositions of lysine, proline, ascorbate, and their derivatives and synthetic analogues and vitamins, pro-vitamins and trace elements.
REFERENCES:
patent: 5198465 (1993-03-01), Dioguardi
patent: 5278189 (1994-01-01), Rath et al.
patent: 5626883 (1997-05-01), Paul
patent: 5639787 (1997-06-01), Riordan et al.
patent: 5650418 (1997-07-01), Rath et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5962517 (1999-10-01), Murad
patent: 34 40 090 (1984-11-01), None
patent: 4243363 (1994-06-01), None
patent: 0 891 771 (1997-07-01), None
patent: 1 068 868 (1997-07-01), None
patent: 891 771 (1999-01-01), None
patent: 2 753 098 (1996-09-01), None
patent: 2 029 220 (1980-03-01), None
patent: 2 268 871 (1994-01-01), None
patent: 62048622 (1987-03-01), None
patent: 4243825 (1992-08-01), None
patent: 6256184 (1994-09-01), None
patent: 91/19488 (1991-12-01), None
patent: 94/01006 (1994-01-01), None
patent: 95/28084 (1995-10-01), None
patent: 00/07607 (2000-02-01), None
patent: 01/22958 (2001-04-01), None
CA132:156872, Kosab, WO 2000007607 A1, 2/1000, abstract.
Strickland, S., et al., (1976) J. Biol. Chem. 751:5694-5702.
Unkeless, et al. (1974) J. Biol. Chem. 249:4295-4305.
Skriver, et al. (1984) J. Cell Biol. 99:753-758.
Corasanti, et al. (1980) J. Natl. Canc. Inst. 65:345-351.
Ladehoff, A. (1962) Act, Path. Micro. Scand. 55:273-280.
Brown, M., et al., (1987) Nature 330: 113-114.
McLean, J.W., et al.(1987) Nature 300:132-137.
Eaton, D.L., (1987) Proc. Natl. Acad. Sol. USA 84:3224-3228.
Salonen, E.,et al. (1989) EMBO J. 8:4035-4040.
Harpel, P.C. et al.(1989) Proc. Natl. Acad. Sci. USA 86:3847-3851.
Gonzalez-Gronow, M. et al.(1989) Biochemistry 28:2374-2377.
Miles, L. et al.(1989) Nature 339:301-302.
Hajjar, K.A., et al.(1989) Nature 339:303-305.
Knox, E.A. (1973) Lancet, i.e. 1465-1467.
Wright, L.C. et al. (1989) Int. J. Cancer 43:241-244.
Rath, M. & L. Pauling (1990) Proc. Natl. Acad. Sci. USA 87:6204-6207.
Marcus, G. (1984) Sem. Thromb. Hemost. 10:61-70.
Nathan, C. (1987) J. Clin. Invest. 79:319-326.
Murad, et al. 1981 Proc. Natl. Acad. Sci. USA 78:2879-2882.
Yonemoto, et al.1976 Proc. Amer. Assoc. Canc. Res. 17:288.
Aoki, N. et al. (1978) Blood 52:1-12.
Katz, E.A., “Reduction of Cholesterol and Lp(a) and Regression of Coronary Artery Disease: A Case Study”Journal of Orthomolecular Medicinepp. 173-179, 11/3, 1996.
Conner, W.E., “What Role for Dietary Supplements in Preventing Coronary Heart Disease?”Consultantp. 1413 38/6 1998.
Mukhopadhyay, C.K., et al “Free Metal Ion-independent Oxidative Damage of Collagen”The Journal of Biological Chemistrypp. 30200-30205, vol. 269, No. 48, 1994.
Tinker, D. et al. “Role of Selected Nutrients in Synthesis, Accumulation, and Chemical Modification of Connective Tissue Proteins”Physiological Reviewspp. 607-657, vol. 65, No. 3, 1985.
Murad, S. et al. “Collagen Synthesis in Cultured Human Skin Fibroblasts: Effect of Ascorbic Acid and Its Analogs”The Journal of Investigative Dermatologypp. 158-162, vol. 81 No. 2, 1983.
Bostom, A.G., et al. “The Effect of High-Dose Ascorbate Supplementation on Plasma Lipoprotein(a) Levels in Patients With Premature Coronary Heart Disease”Pharmaco Therapypp. 458-464, vol. 15, No. 4, 1995.
Tardif, J-C et al. “Probucol and Multivitamins in the Prevention of Restenosiss After Coronary Angioplasty”The New England Journal of Medicinepp. 365-372, vol. 337, No. 6, 1997.
Rath, Matthias, M.D. et al. “Nutritional Supplement Program Halts Progression of Early Coronary Atherosclerosis, Documented by Ultrafast Computed Tomography”The Journal of Applied Nutrition, vol. 48, No. 3, 1996.
LandOfFree
Synergistic compositions comprising ascobate and lysine for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic compositions comprising ascobate and lysine for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic compositions comprising ascobate and lysine for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469065